Related Experiment Video
Updated: Feb 4, 2026

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
Published on: May 24, 2014
A pharmacological probe identifies cystathionine β-synthase as a new negative regulator for ferroptosis
Li Wang1, Hao Cai2, Youtian Hu1
1Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
Cystathionine β-synthase (CBS) is responsible for the first enzymatic reaction in the transsulfuration pathway of sulfur amino acids. The molecular function and mechanism of CBS as well as that of transsulfuration pathway remain ill-defined in cell proliferation and death. In the present study, we designed, synthesized and obtained a bioactive inhibitor CH004 for human CBS, which functions in vitro and in vivo. CH004 inhibits CBS activity, elevated the cellular homocysteine and suppressed the production of hydrogen sulfide in a dose-dependent manner in cells or in vivo. Chemical or genetic inhibition of CBS demonstrates that endogenous CBS is closely coupled with cell proliferation and cell cycle. Moreover, CH004 substantially retarded in vivo tumor growth in a xenograft mice model of liver cancer. Importantly, inhibition of CBS triggers ferroptosis in hepatocellular carcinoma. Overall, the study provides several clues for studying the interplays amongst transsulfuration pathway, ferroptosis and liver cancer.
Insights
A novel inhibitor, CH004, targets cystathionine β-synthase (CBS) to suppress liver cancer growth. Inhibiting CBS disrupts the transsulfuration pathway, leading to ferroptosis and reduced tumor progression.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cystathionine β-synthase (CBS) catalyzes the initial step in sulfur amino acid transsulfuration.
- The roles of CBS and the transsulfuration pathway in cell proliferation and death are not fully understood.
Purpose of the Study:
- To investigate the function and mechanism of CBS in cell proliferation and death.
- To develop and characterize a novel CBS inhibitor for potential therapeutic applications in liver cancer.
Main Methods:
- Design, synthesis, and in vitro/in vivo validation of a bioactive CBS inhibitor (CH004).
- Assay of CBS activity, homocysteine levels, and hydrogen sulfide production.
- Inhibition of CBS via chemical or genetic means.
- Evaluation of CH004 efficacy in a liver cancer xenograft mouse model.
Main Results:
- CH004 effectively inhibits human CBS activity in vitro and in vivo.
- CH004 treatment led to increased cellular homocysteine and decreased hydrogen sulfide production in a dose-dependent manner.
- CBS inhibition was found to be coupled with cell proliferation and cell cycle regulation.
- CH004 significantly suppressed tumor growth in a liver cancer xenograft model.
- Inhibition of CBS induced ferroptosis in hepatocellular carcinoma cells.
Conclusions:
- Endogenous CBS plays a critical role in liver cancer cell proliferation.
- Inhibition of CBS by CH004 represents a potential therapeutic strategy for liver cancer by inducing ferroptosis.
- The study highlights the intricate connections between the transsulfuration pathway, ferroptosis, and liver cancer.
Related Concept Videos
Negative Regulator Molecules
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
ATP Synthase: Structure
ATP Synthase: Mechanism
Positive, Negative, and Zero Work
Epigenetic Regulation

